

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 0575/55424-A-PCT-US	Serial No. 09/689,469
AUG 13 2001		INFORMATION DISCLOSURE STATEMENT (TRADEMARK sheets if necessary)		Applicant Ann Marie Schmidt, et al.	AUG 23 2001
				Filing Date October 12, 2000	Group 1646
RECEIVED TECH CENTER 1600/29					

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CY		5 8 6 4 0 1 8	4/16/96	Morser et al.			
CY		5 5 8 5 3 4 4		Vlassara et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
CY	WO	9 8 2 2 1 3 8	5/28/98	PCT				
CY	WO	9 7 3 9 1 2 1	10/23/97	PCT				
CY	WO	9 7 3 9 1 2 5	10/23/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Hori et al. 'The Receptor for Advanced Glycation Endproducts: Implications for the Development of Diabetic Vascular Disease. Fundam. Clin. Cardiol.' In: The Endothelium in Clinical Practice. January 1997, Chapter 11, pages 311-329;
	Chen et al. Amyloid-beta Peptide- Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease. Proc. Natl. Acad. Sci. 13 May 1997, Vol. 94, No. 10, pages 5296-5301;
	Schmidt et al. V-domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications. Circulation. 21 October 1997, Vol. 96, No. 8 Suppl., page I37;
	Hori et al. The Receptor for Advanced Glycation Endproducts (RAGE) Is A Cell Surface Receptor for Amphotericin in the Developing Central Nervous System (CNS) to Promote Neurite Outgrowth. FASEB J. 1995, Vol. 9, No. 3, page A382; <i>Not her</i>

EXAMINER	DATE CONSIDERED
----------	-----------------

Christopher

DATE CONSIDERED

4/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

AUG 13 2001

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No. 0575/55424-A-PCT-US Serial No. 09689,469

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant

Ann Marie Schmidt, et al.

Filing Date

October 12, 2000

Group

1646

RECEIVED

AUG 23 2001

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TECH CENTER 1600/2C

International Search Report of International Application No.

PCT/US99/08427, dated July 29, 1999;

CY Park, L., et al. (1998) "Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE)" Nature Medicine, 4:1025-1031;

CY Vlassara, H., et al. (1995) "Identification of Galectin-2 as a high affinity binding protein for Advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex" Molecular Medicine, 1:634-646;

CY Yan S-D, Chen X, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern DM, Schmidt A-M: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-691.

EXAMINER

DATE CONSIDERED

Cheng WH Yn

4/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.